Bronchogen is a synthetic short bioregulatory tetrapeptide studied extensively in preclinical models of pulmonary physiology, cellular repair, and inflammatory modulation. Laboratories seeking to buy Bronchogen BALF composition for sale require analytical-grade purity, lot-specific verification, and reliable stability to measure bronchoalveolar lavage fluid markers with high precision. PX1 Research provides fully documented, USA-manufactured research peptides tailored strictly for qualified in vitro and animal research environments.
Bronchogen is a synthetic short bioregulatory tetrapeptide studied extensively in preclinical models of pulmonary physiology, cellular repair, and inflammatory modulation. Laboratories seeking to buy Bronchogen BALF composition for sale require analytical-grade purity, lot-specific verification, and reliable stability to measure bronchoalveolar lavage fluid markers with high precision. PX1 Research provides fully documented, USA-manufactured research peptides tailored strictly for qualified in vitro and animal research environments.
Researchers looking to buy Bronchogen for BALF composition analysis require high-purity, laboratory-grade tetrapeptide (Ala-Asp-Glu-Leu) specifically synthesized for in vitro and animal models of pulmonary function. Sourcing Bronchogen for evaluating bronchoalveolar lavage fluid parameters ensures accurate measurement of inflammatory cell counts, cytokine expression, and tissue integrity without sample contamination.
When evaluating options to buy Bronchogen BALF composition for sale, investigators must prioritize analytical purity and rigorous quality control. Bioregulatory peptides used in respiratory studies act on subtle genetic and cellular signaling cascades; thus, minor impurities, residual solvents, or endotoxin contamination can obscure experimental outcomes. PX1 Research supplies standardized research peptides manufactured under ISO 17025 laboratory standards to guarantee reproducibility across all preclinical assays.
Bronchogen is a short peptide chain composed of four amino acids: L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu). Derived from bioregulatory peptide research pioneered in peptide-mediated gene regulation, Bronchogen belongs to a class of short signal peptides designed to interact directly with chromatin structure and specific histone-DNA complexes within cell nuclei.
With a molecular weight of approximately 460.48 g/mol, the low-molecular-weight tetrapeptide displays high aqueous solubility and predictable chemical stability when stored under proper conditions. In vitro data indicate that its specific carboxyl and amine terminal configurations permit targeted binding to gene promoter regions regulating bronchial epithelial homeostasis and structural protein expression.
Preclinical studies suggest that Bronchogen operates primarily by modulating gene expression in bronchial epithelial cells, lung fibroblasts, and alveolar macrophages. Animal models subjected to acute or chronic pulmonary stressors demonstrate that exposure to Bronchogen alters transcriptional activity associated with inflammatory cascades, extracellular matrix remodeling, and oxidative stress pathways.
In rodent models of induced bronchial constriction and chronic airway inflammation, researchers observe that Bronchogen administration correlates with decreased epithelial hyperplasia and restored ciliary clearing activity. By interacting with nucleosomal proteins, the peptide appears to epigenetically regulate the synthesis of protective lung proteins, reducing local tissue degradation and microvascular permeability during challenge assays.
Bronchoalveolar Lavage Fluid (BALF) composition analysis serves as a primary quantitative endpoint in preclinical respiratory investigations. By collecting fluid lavaged from the pulmonary tree, investigators evaluate the exact cellular and biochemical profile of the mucosal interface, assessing how candidate compounds alter inflammatory cell infiltration.
When testing Bronchogen in pulmonary challenge models, changes in BALF composition provide critical baseline data. Key parameters measured in BALF after peptide treatment include total and differential cell counts (macrophages, neutrophils, lymphocytes, and eosinophils), total protein concentrations, lactate dehydrogenase (LDH) activity as a marker of cytotoxicity, and specific surfactant phospholipid levels. High-purity Bronchogen ensures that observed shifts in BALF markers reflect true biological responses rather than reactions to synthetic artifacts.
In addition to cellular counts, advanced BALF composition assays quantify key pro-inflammatory and anti-inflammatory cytokines using multiplex ELISA or bead-based immunoassay platforms. Preclinical data indicate that Bronchogen administration modulates the expression of pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8/KC) within the bronchoalveolar space.
Simultaneously, researchers track changes in anti-inflammatory markers like interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). By analyzing these cytokine networks in BALF samples, laboratory teams can map the precise pathway through which short bioregulatory peptides attenuate hyper-inflammatory cell recruitment and preserve alveolar capillary membrane stability. Further details on experimental design can be explored in our peptide research hub.
Understanding how Bronchogen fits within the broader landscape of short bioregulatory peptides requires direct comparison with related laboratory compounds. Researchers frequently examine Bronchogen alongside other tissue-specific signal peptides to compare organ-specific expression patterns and systemic immune modulation capabilities.
For instance, Chonluten respiratory research focuses on a tripeptide sequence (Glu-Asp-Gly) targeting pulmonary and bronchial tissue through similar gene regulatory mechanisms. In contrast, studies involving Thymogen immune mechanisms evaluate a dipeptide (Glu-Trp) centered on T-cell maturation and systemic immunomodulation rather than tissue-localized mucosal defense. Meanwhile, non-bioregulatory cytoprotective agents like BPC-157 cytoprotective mechanisms act primarily via angiogenic and growth factor up-regulation rather than direct nuclear histone interaction. Sourcing pure compounds across these classes enables rigorous comparative assays in pulmonary pathology.
To preserve structural integrity and prevent degradation, lyophilized Bronchogen must be handled according to strict laboratory protocols. Upon receipt, the lyophilized cake should be stored in a freezer at -20°C or -80°C until reconstitution. Avoid unnecessary freeze-thaw cycles, which can induce peptide cleavage or aggregation.
Reconstitution should be performed using sterile, bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) under a laminar flow hood. Gently swirl or invert the vial until complete dissolution is achieved; never vortex high-purity peptide solutions vigorously. Once reconstituted, aliquot the solution into single-use microcentrifuge tubes and store at -20°C or below for working experimental timelines.
Validating peptide purity is essential for publishing reproducible preclinical data. Every batch of Bronchogen offered for laboratory research must undergo comprehensive analytical testing, including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity levels exceeding 98%.
Mass Spectrometry (MS) confirms exact molecular weight and amino acid sequence identity, ensuring the absence of deletion sequences or incomplete synthesis products. Furthermore, because BALF assays are highly sensitive to bacterial lipopolysaccharides, stringent Chromogenic LAL (Limulus Amebocyte Lysate) endotoxin testing must confirm levels well below standard threshold limits (< 0.1 EU/mg). PX1 Research supplies a lot-specific Certificate of Analysis (COA) with every shipment.
Securing consistent, high-grade reagents is vital for academic, pharmaceutical, and biotechnology research facilities. When laboratories order compounds for quantitative BALF composition studies, vendor selection relies on batch-to-batch consistency, transparent documentation, and rapid, temperature-controlled distribution.
PX1 Research manufactures all research peptides in USA-based, GMP-compliant facilities. Orders are fulfilled directly from our California and Arizona logistics hubs with same-day dispatch (Monday through Friday). Principal investigators and laboratory procurement officers seeking bulk quantities or standardized contract supply can explore custom institutional arrangements via our wholesale research accounts.
What is Bronchogen used for in laboratory research?
Bronchogen (Ala-Asp-Glu-Leu) is synthesized strictly for in vitro and preclinical animal research evaluating bronchial epithelial function, cellular gene expression, and changes in bronchoalveolar lavage fluid (BALF) composition during pulmonary challenge models.
How does Bronchogen influence BALF cellular composition in preclinical models?
In animal models of lung inflammation, Bronchogen administration has been observed to modulate overall cell counts in BALF, specifically reducing neutrophil infiltration and altering macrophage activation states.
What analytical methods verify the purity of Bronchogen?
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity levels >98%, Mass Spectrometry (MS) to verify molecular mass, and LAL assays to ensure low endotoxin levels.
How should lyophilized Bronchogen be stored upon delivery?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment protected from light to maintain long-term stability prior to reconstitution.
What diluent is recommended for reconstituting Bronchogen for cell culture assays?
For cell culture or in vitro assays, sterile, endotoxin-free phosphate-buffered saline (PBS, pH 7.4) or sterile water for injection (WFI) is recommended under sterile laminar flow conditions.
Does PX1 Research provide a Certificate of Analysis (COA) with Bronchogen?
Yes. Every lot of Bronchogen supplied by PX1 Research includes a third-party Certificate of Analysis (COA) detailing RP-HPLC purity charts, Mass Spectrometry verification, and endotoxin assay results.
How does Bronchogen differ from Chonluten?
While both are bioregulatory short peptides targeting respiratory models, Bronchogen is a tetrapeptide (Ala-Asp-Glu-Leu) and Chonluten is a tripeptide (Glu-Asp-Gly). They exhibit distinct binding profiles and gene regulatory interactions in bronchial tissue models.
Is Bronchogen approved for human therapeutic or clinical use?
No. Bronchogen supplied by PX1 Research is strictly for laboratory research use only in qualified institutional environments. It is not intended for human consumption, clinical diagnosis, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.